CN113166721A - 抑郁症治疗方法和药物 - Google Patents
抑郁症治疗方法和药物 Download PDFInfo
- Publication number
- CN113166721A CN113166721A CN201980076664.7A CN201980076664A CN113166721A CN 113166721 A CN113166721 A CN 113166721A CN 201980076664 A CN201980076664 A CN 201980076664A CN 113166721 A CN113166721 A CN 113166721A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- depression
- glur2
- subject
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title abstract description 13
- 238000011282 treatment Methods 0.000 title description 11
- 208000020401 Depressive disease Diseases 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 99
- 229920001184 polypeptide Polymers 0.000 claims abstract description 97
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 97
- 208000024714 major depressive disease Diseases 0.000 claims abstract description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 206010010144 Completed suicide Diseases 0.000 claims description 21
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims description 9
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 230000009182 swimming Effects 0.000 description 14
- 239000000935 antidepressant agent Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000001430 anti-depressive effect Effects 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 101710149951 Protein Tat Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical class C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 206010065604 Suicidal behaviour Diseases 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042458 Suicidal ideation Diseases 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000004594 appetite change Effects 0.000 description 2
- -1 coatings Substances 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 229960000450 esketamine Drugs 0.000 description 2
- 238000012048 forced swim test Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002898 effect on depression Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
一种抑郁症治疗方法和药物。具体而言，一种GluR2‑CT多肽在治疗抑郁症，特别是重度抑郁症的用途。
Description
PCT国内申请，说明书已公开。
Claims (9)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811390067 | 2018-11-21 | ||
| CN2018113900675 | 2018-11-21 | ||
| PCT/CN2019/119855 WO2020103889A1 (zh) | 2018-11-21 | 2019-11-21 | 抑郁症治疗方法和药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113166721A true CN113166721A (zh) | 2021-07-23 |
Family
ID=70774338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980076664.7A Pending CN113166721A (zh) | 2018-11-21 | 2019-11-21 | 抑郁症治疗方法和药物 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20220347266A1 (zh) |
| CN (1) | CN113166721A (zh) |
| WO (1) | WO2020103889A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO135590A1 (ro) * | 2020-08-31 | 2022-03-30 | Szedlacsek Ştefan Eugen | Peptide de interferenţă ca inhibitori ai interacţiunilor legate de endocitoza receptorilor ampa |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961325A (zh) * | 2010-10-29 | 2011-02-02 | 西南交通大学 | 大黄素在制备治疗抑郁症药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030051266A1 (en) * | 2001-02-14 | 2003-03-13 | Serafini Tito Andrew | Collections of transgenic animal lines (living library) |
| WO2010083338A2 (en) * | 2009-01-14 | 2010-07-22 | Philadelphia Health And Education Corporation | Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease |
| CN106632601B (zh) * | 2016-11-16 | 2020-10-20 | 中国科学院昆明动物研究所 | 一种阻断突触长时程增强（ltp）的短肽及其应用 |
-
2019
- 2019-11-21 CN CN201980076664.7A patent/CN113166721A/zh active Pending
- 2019-11-21 WO PCT/CN2019/119855 patent/WO2020103889A1/zh active Application Filing
- 2019-11-21 US US17/436,900 patent/US20220347266A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961325A (zh) * | 2010-10-29 | 2011-02-02 | 西南交通大学 | 大黄素在制备治疗抑郁症药物中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| YANZHI YU ET AL.: "Facilitated AMPAR endocytosis causally contributes to the maternal sleep deprivation-induced impairments of synaptic plasticity and cognition in the offspring rats", 《NEUROPHARMACOLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020103889A1 (zh) | 2020-05-28 |
| US20220347266A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Black et al. | Challenges in the development of therapeutics for narcolepsy | |
| US20200353054A1 (en) | Use of ave0010 for the treatment of diabetes mellitus type 2 | |
| JP6329487B2 (ja) | ２型糖尿病の治療プロトコル | |
| ES2330671T3 (es) | Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos. | |
| Weitgasser et al. | Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study | |
| CN107847615B (zh) | 用于治疗cln2疾病的tpp1调配物及方法 | |
| US20090048288A1 (en) | Method of treating stress-mediated depression | |
| TW200800158A (en) | Methods for neuroprotection | |
| US7723302B2 (en) | Method of treating Parkinson's disease | |
| CN109069595A (zh) | 标靶医疗性溶酶体酵素融合蛋白质、其相关调配物与用途 | |
| CN104105501B (zh) | 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗 | |
| CN113166721A (zh) | 抑郁症治疗方法和药物 | |
| WO2004080476A1 (en) | Use of secretin in the treatment of schizophrenia | |
| CN110548132B (zh) | TGF-β1蛋白在制备治疗抑郁症的药物中的应用 | |
| US20010053795A1 (en) | Paradoxical pharmacology | |
| CN114191422A (zh) | 根皮素在制备抗抑郁药物中的应用 | |
| CN102526764A (zh) | 一种猴重度全身性帕金森病模型及其药物筛选方法 | |
| US20130090289A1 (en) | Method of Treatment of Type 2 Diabetes | |
| Langford et al. | PDB13-SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 INHIBITORS AND METFORMIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 1 DIABETES | |
| Jaramillo et al. | Differential effect on two immobility responses by chronic administration of 1, 3-di-o-tolyl-guanidine (sigma receptor agonist) in rats with neonatal ventral hippocampal lesion | |
| Zhou et al. | PDB16-COMPARE RENAL FUNCTIONAL PRSERVATION OUTCOME OF SGLT2 INHIBITOR VS DPP4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY OF JAPANESE COMMERCIAL DATABASE WITH ADVANCED ANALYTICS APPROACH | |
| Thannickal et al. | Pleasure, addiction, and hypocretin (orexin). | |
| Argyriou et al. | Cocaine use and abuse triggering sporadic young-onset amyotrophic lateral sclerosis | |
| JP2017088584A (ja) | 医薬組成物 | |
| TW202417035A (zh) | 提派肽(tirzepatide)組合物及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210723 |
|
| WD01 | Invention patent application deemed withdrawn after publication |